Advertisement

Topics

Avedro Announces Agreement with the FDA for the First U.S. Pivotal Phase 3 Trial of an Epi-on Cross-Linking Treatment for Patients with Progressive Keratoconus

08:00 EDT 15 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Procedure Includes New Drug Formulation and Use of Oxygen Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has reached agreement...

Other Sources for this Article

Avedro Contact:
Avedro, Inc.
David Iannetta, 781-768-3400
info@avedro.com
or
Media Contact:
Gray Communications, LLC.
Michele Gray, 917-449-9250
michele_gray@me.com

NEXT ARTICLE

More From BioPortfolio on "Avedro Announces Agreement with the FDA for the First U.S. Pivotal Phase 3 Trial of an Epi-on Cross-Linking Treatment for Patients with Progressive Keratoconus"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...